Page last updated: 2024-09-04
pralnacasan and chloroquine
pralnacasan has been researched along with chloroquine in 2 studies
Compound Research Comparison
Studies (pralnacasan) | Trials (pralnacasan) | Recent Studies (post-2010) (pralnacasan) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
---|---|---|---|---|---|
19 | 0 | 7 | 16,405 | 763 | 4,029 |
Protein Interaction Comparison
Protein | Taxonomy | pralnacasan (IC50) | chloroquine (IC50) |
---|---|---|---|
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
Procathepsin L | Homo sapiens (human) | 5.47 | |
Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
Beta-secretase 1 | Homo sapiens (human) | 7 | |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Reviews
1 review(s) available for pralnacasan and chloroquine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
1 other study(ies) available for pralnacasan and chloroquine
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |